These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 39294513)

  • 1. Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes.
    Zhao J; Guo H; Wu C; Guo H
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39294513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effectiveness of chemotherapy combined with immunotherapy and chemotherapy alone in advanced biliary tract cancer and construction of the nomogram for survival prediction based on the inflammatory index and controlling nutritional status score.
    Zhang Z; Wang D; Zhang J; Ruan Y; Zhao L; Yang L; Liu Z; Yang L; Lou C
    Cancer Immunol Immunother; 2023 Nov; 72(11):3635-3649. PubMed ID: 37668711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
    Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
    Front Immunol; 2022; 13():801909. PubMed ID: 35309350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma.
    Zeng J; Ma J; Zeng Z; Yang L; Jiang Y; Mo N; Ma F; Liu C; Li R; Tang J; Qin S; Jiang H
    J Gastrointest Oncol; 2023 Apr; 14(2):758-767. PubMed ID: 37201053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
    Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
    Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
    Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
    Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
    Chen X; Wu X; Wu H; Gu Y; Shao Y; Shao Q; Zhu F; Li X; Qian X; Hu J; Zhao F; Mao W; Sun J; Wang J; Han G; Li C; Xia Y; Seesaha PK; Zhu D; Li H; Zhang J; Wang G; Wang X; Li X; Shu Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33172881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
    Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
    Hepatol Int; 2024 Aug; 18(4):1286-1298. PubMed ID: 38717693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis.
    Wang F; Wang FH; Sun K; Jiang C; Peng S; Xu LX; Kuang M; Guo GF; Chen SL
    J Inflamm Res; 2022; 15():6031-6046. PubMed ID: 36339826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
    Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of camrelizumab plus chemotherapy versus chemotherapy alone in patients with untreated, HER2-negative, unresectable locally advanced, or metastatic gastric cancer or gastroesophageal junction cancer: a retrospective comparative cohort study.
    Xiang J; Gong W; Sun P; Wang X; Liu A
    J Gastrointest Oncol; 2022 Dec; 13(6):2874-2884. PubMed ID: 36636085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic and predictive significance of circulating biomarkers in patients with advanced upper gastrointestinal cancer undergoing systemic chemotherapy.
    Li N; Gao L; Ge Y; Zhao L; Bai C; Wang Y
    Front Oncol; 2023; 13():1195848. PubMed ID: 37346066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit and biomarker of PD-1 inhibitor combination therapy in first-line of advanced biliary tract cancer: A retrospective study.
    Guo J; Zhou Q; Zhou M; Dai H; Li L; Qiu Y; Mao L; Liu B; Shen J
    Cancer Med; 2023 Nov; 12(22):20699-20711. PubMed ID: 37930138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
    Chen X; Qin S; Gu S; Ren Z; Chen Z; Xiong J; Liu Y; Meng Z; Zhang X; Wang L; Zhang X; Zou J
    Int J Cancer; 2021 Dec; 149(11):1944-1954. PubMed ID: 34309846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors.
    Zhang Z; Wang D; Yang L; Zhao L; Yang L; Zhang J; Lou C
    Cancer Med; 2023 Jul; 12(14):15217-15228. PubMed ID: 37392168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative.
    Li T; Chen C; Liu L; Qin J; Qiu L; Wang A; Dong W; Zhang G; Li Y; Zhao L; Zhang F; Hu Y
    Cancer Med; 2024 Feb; 13(3):e7024. PubMed ID: 38400661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy.
    Ao M; Li P; Sun D; Li X; Xu S; Hao Y
    J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.
    Chu Y; He X; Xue Y; Jiang H; Zhu C; Qi C; Zhang X; Chen D; Dai H; Xian Q; Zhu W
    Front Immunol; 2024; 15():1448485. PubMed ID: 39253086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
    Wang X; Liu X; Dai H; Jia J
    BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.